Other news

Categories
Top Dollar Euro Gold Silver Gas Oil Bitcoin Ethereum S&P 500 DAX Other

No change of the indicator value may reduce the volatility of the related markets.

28 January
Bank of Canada set for another big rate hike

The Bank of Canada is expected to announce another interest rate hike by 75 basis points today, marking a 14-year high. High inflation outweighs a possible recession.

26 October 2022
Alphabet investors are worried about rising digital ad prices

On Tuesday, worries in the digital media sector were caused by disappointing ad sales at Alphabet Inc.

26 October 2022
Coca-Cola exceeded expectations and improved its predictions for the rest of the year

On Tuesday, Coca-Cola Co. raised its annual forecasts, adding to competitor PepsiCo Inc.

26 October 2022
Australian inflation has accelerated to a 32-year high

The consumer price index in Australia, which grew by 7.3%, reached the highest value since 1990. Over the past quarter, core inflation increased by 6.1%, also the highest since 2003.

26 October 2022
Walmart to raise up to $3 billion for Flipkart

Flipkart, a subsidiary of Walmart, is planning an expansion in India to successfully stand up to competitors. It will need about $3 billion to increase its product offerings.

26 October 2022
Dollar falls amid heightened expectations of less hawkish Fed policy

According to Reuters, the price of the dollar concerning basic currencies has fallen to a three-week low.

26 October 2022
Xerox shares fall amid pessimistic forecasts

Xerox Holdings Inc shares fell about 25% on Tuesday. The drop in the company's stock came after the photocopy maker cut its annual earnings and cash flow forecast.

26 October 2022
Johnson & Johnson’s medicine has been approved for blood cancer therapy

The U.S. Food and Drug Administration (FDA) has approved a medicine (teclistamab) produced by Johnson & Johnson for therapy of multiple myeloma, or the type of blood cancer. Prior to this, the medicine has already been conditionally approved by the European drug regulator in August.

26 October 2022
Microsoft shares fall amid forecasts of weak Azure growth

Microsoft shares fell due to weak sales of the Azure platform. Microsoft Chief Financial Officer Amy Hood estimates Azure revenue growth will be 37% in the current quarter, down 5% from the third quarter. Last quarter, Azure sales were up 42%.

26 October 2022
Visa Q4 results exceed expectations

Financial results, which exceeded all expectations, were published by Visa Corporation for the fourth quarter.

26 October 2022